{
    "clinical_study": {
        "@rank": "132656", 
        "arm_group": {
            "arm_group_label": "BIAsp", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial investigate the the long-term\n      safety of biphasic insulin aspart 30 in subjects with type 2 diabetes."
        }, 
        "brief_title": "Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen\u2122 in Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent obtained before any trial-related activities\n\n          -  Completed the trial BIAsp-1236\n\n        Exclusion Criteria:\n\n          -  Planned changes in use of any prescription medication that may interfere with glucose\n             regulation\n\n          -  Known or suspected allergy to trial products or related products\n\n          -  Women who are having the intention of becoming pregnant, or are judged not to be\n             using adequate contraceptive measures\n\n          -  Any other significant condition or concomitant disease or any condition that would\n             interfere with participation as judged by the Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "89", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704378", 
            "org_study_id": "BIASP-1386"
        }, 
        "intervention": {
            "arm_group_label": "BIAsp", 
            "description": "Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal", 
            "intervention_name": "biphasic insulin aspart", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin", 
                "Insulin, NPH"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 8, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lahti", 
                        "country": "Finland", 
                        "zip": "15850"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kongsvinger", 
                        "country": "Norway", 
                        "zip": "2212"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Motala", 
                        "country": "Sweden", 
                        "zip": "591 85"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom", 
                        "zip": "EH16 4SA"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Finland", 
                "Norway", 
                "Sweden", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-National, Multi-Centre, Open-Labelled Extension Study Assessing the Long-Term Safety of Biphasic Insulin Aspart 30 in NovoMix\u00ae30 FlexPen\u2122 in Type 2 Diabetic Patients Previously Treated in BIAsp-1236", 
        "overall_official": {
            "affiliation": "Novo Nordisk Scandinavia AB", 
            "last_name": "Britt Sundberg", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Finland: Finnish Medicines Agency", 
                "Norway: Norwegian Medicines Agency", 
                "Sweden: Medical Products Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Hypoglycaemic episodes", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Occurrence of adverse events", 
                "safety_issue": "No"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704378"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "HbA1c (glycosylated haemoglobin)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Prandial increment in blood glucose", 
                "safety_issue": "No"
            }, 
            {
                "measure": "7-point blood glucose profile", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}